Media headlines about Cyclacel Pharmaceuticals (NASDAQ:CYCC) have trended somewhat positive on Saturday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cyclacel Pharmaceuticals earned a news sentiment score of 0.08 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.8776503019124 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

NASDAQ:CYCC traded up $0.10 on Friday, reaching $1.53. 116,043 shares of the stock traded hands, compared to its average volume of 70,419. Cyclacel Pharmaceuticals has a 1-year low of $1.28 and a 1-year high of $2.27.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its earnings results on Thursday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). sell-side analysts expect that Cyclacel Pharmaceuticals will post -0.53 EPS for the current year.

Several research analysts have recently issued reports on CYCC shares. Roth Capital started coverage on Cyclacel Pharmaceuticals in a research note on Wednesday. They issued a “buy” rating and a $8.00 price objective for the company. HC Wainwright set a $7.00 target price on shares of Cyclacel Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 10th. Zacks Investment Research raised shares of Cyclacel Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 17th. Finally, LADENBURG THALM/SH SH assumed coverage on shares of Cyclacel Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $6.25 target price for the company. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Cyclacel Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $5.75.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.

Recommended Story: Asset Allocation Models, Which is Right For You?

Insider Buying and Selling by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with's FREE daily email newsletter.